Feed UTHR
UT

United Therapeutics

UTHR · NASDAQ

$497.11 -1.68% (-$8.49)
1M -2.24%
Market Cap $21.1B
P/E Ratio 16.10x
Div. Yield -
ROE 20.18%

Bulios Fair Price

$500.42

0.7% upside

Trenutna cena

$497.11

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica UTHR trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
6/9
Valuation
64 /100
Fair
P/E 16.10x
PEG 1.35x
EV/EBITDA 11.68x
Growth
96 /100
Growing
EPS growth 22.92%
Book val. growth 13.94%
Rev. growth 18.02%
Profitability
100 /100
Strong
Gross margin 86.14%
FCF margin 34.65%
Net margin 41.56%
Quality
84 /100
Excellent
ROIC 17.69%
Asset turnover 0.44x
ROE 20.18%
Debt
100 /100
Low
Debt/Equity 0.00x
Net debt/EBITDA -1.09x
Current ratio 5.73x
Stability
98 /100
Stable
Beta 0.56x
Profitable years 6
Rev. volatility 6.75%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o UTHR
Online

O podjetju

United Therapeutics Corporation is an American biotechnology company headquartered in Silver Spring, Maryland. The company focuses on the development and manufacturing of drugs for the treatment of pulmonary arterial hypertension and other pulmonary and vascular-related diseases. Their main drugs include therapies for the treatment of pulmonary arterial hypertension and carcinoid syndrome. United Therapeutics is also involved in research and development of new drug formulations in the field of regenerative medicine and organ transplantation. The company is known for its innovative approach to treating pulmonary diseases and comprehensive research in the field of biotechnology. Shares of United Therapeutics Corporation are publicly traded on the NASDAQ stock exchange.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Martine A. Rothblatt

Employees

1,400

Headquarters

Silver Spring

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

51d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.